0 600

Cited 5 times in

The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer

 Ji Soo Park  ;  Jae-Seok Lee  ;  Eun Young Kim  ;  Ji Ye Jung  ;  Se Kyu Kim  ;  Joon Chang  ;  Dae Joon Kim  ;  Chang Young Lee  ;  Inkyung Jung  ;  Joo Hang Kim  ;  Hye Ryun Kim  ;  Yong Wha Moon  ;  Hyo Song Kim  ;  Byoung Chul Cho  ;  Hyo Sup Shim 
 LUNG CANCER, Vol.88(3) : 325-331, 2015 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Female ; Follow-Up Studies ; Gene Amplification* ; Humans ; In Situ Hybridization, Fluorescence ; Lung Neoplasms/genetics* ; Lung Neoplasms/mortality* ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Outcome Assessment (Health Care) ; Prognosis ; Receptor, Fibroblast Growth Factor, Type 1/genetics* ; Republic of Korea ; Risk Factors ; Small Cell Lung Carcinoma/genetics* ; Small Cell Lung Carcinoma/mortality* ; Small Cell Lung Carcinoma/pathology
Amplification ; Biomarker ; FGFR1 ; FISH ; Prognosis ; Small cell lung cancer
OBJECTIVES: Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency of FGFR1 amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance of FGFR1 amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies.

MATERIALS AND METHODS: Tumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using an FGFR1 FISH assay with a probe that hybridized to chromosome region 8p12-8p11.23 (Abbott Molecular, Abbott Park, IL).

RESULTS AND CONCLUSION: FGFR1 amplification was detected in three patients (1.9%) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR]=7.1; 95% confidence interval [CI]=2.0-25.4; P=0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and without FGFR1 amplification, respectively (P=0.37). Although FGFR1 amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply that FGFR1 may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Dae Joon(김대준)
Kim, Se Kyu(김세규)
Kim, Eun Young(김은영) ORCID logo https://orcid.org/0000-0002-3281-5744
Kim, Joo Hang(김주항)
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Park, Ji Soo(박지수) ORCID logo https://orcid.org/0000-0002-0023-7740
Shim, Hyo Sup(심효섭) ORCID logo https://orcid.org/0000-0002-5718-3624
Lee, Chang Young(이창영)
Chang, Joon(장준) ORCID logo https://orcid.org/0000-0003-4542-6841
Jung, Inkyung(정인경) ORCID logo https://orcid.org/0000-0003-3780-3213
Jung, Ji Ye(정지예) ORCID logo https://orcid.org/0000-0003-1589-4142
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.